SCHEMBL644309

SCHEMBL644309

O=C(Cl)c1cc(Br)c(OCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.49
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
FOLH1 Q04609 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MCL1 Q07820 1/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.45
PTGER1 P34995 1/20 0.44
GLRA1 P23415 1/20 0.44
LRRK2 Q5S007 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383569 0.89 FOLH1 (0.60) ABCB1THRATHRBFOLH1L3MBTL1
SCHEMBL590872 0.87 MCL1 (0.48) ABCB1THRATHRBFOLH1L3MBTL1
SCHEMBL2946703 0.85 MAOB (0.57) ABCB1FOLH1L3MBTL1TDP1SMN1; SMN2
SCHEMBL4483528 0.84 ABCB1 (0.48) ABCB1THRATHRBFOLH1L3MBTL1
SCHEMBL31363007 0.84 ALDH1A1 (0.53) ABCB1FOLH1L3MBTL1TDP1RAB9A
SCHEMBL382869 0.84 ALDH1A1 (0.53) ABCB1FOLH1L3MBTL1TDP1RAB9A
SCHEMBL2469286 0.84 MRGPRX4 (0.52) FOLH1RAB9ASMN1; SMN2MCL1ALDH1A1
SCHEMBL646463 0.83 ABCB1 (0.53) ABCB1FOLH1L3MBTL1TDP1RAB9A
SCHEMBL21327204 0.82 MCL1 (0.54) FOLH1L3MBTL1TDP1SMN1; SMN2MCL1
SCHEMBL19361431 0.82 PTGES (0.52) FOLH1MCL1PTGER1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8816070-B2 Triazole derivative as an HSP 90 inhibitor MERCK PATENT GMBH (DE) 2014-08-26 US disclosed
EP-2023922-B1 TRIAZOLE DERIVATIVES II MERCK PATENT GMBH (DE) 2012-07-11 EP disclosed
US-8119795-B2 Triazole derivatives II MERCK PATENT GMBH (DE) 2012-02-21 US disclosed
US-20100113542-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR MERCK PATENT GESELLSCHAFT (DE) 2010-05-06 US disclosed
US-20100022540-A1 TRIAZOLE DERIVATIVES II MERCK PATENT GESELLSCHAFT (DE) 2010-01-28 US disclosed
EP-2023922-A2 TRIAZOLE DERIVATIVES II Merck Patent GmbH (DE) 2009-02-18 EP disclosed
WO-2007134678-A2 TRIAZOLE DERIVATIVES II MERCK PATENT GMBH (DE) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022540-A1 TRIAZOLE DERIVATIVES II HSP90AB1, HSP90AA1, HSP90AB2P ABCB1 44/4885THRA 1358/4885THRB 1374/4885
US-20100113542-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR HSP90AB1, HSP90AB2P, HSP90AA1 ABCB1 263/4885THRA 1478/4885THRB 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.